281 related articles for article (PubMed ID: 18717707)
41. MicroRNAs and target genes in epileptogenesis.
Feng Y; Yang H; Yue Y; Tian F
Epilepsia; 2020 Oct; 61(10):2086-2096. PubMed ID: 32944964
[TBL] [Abstract][Full Text] [Related]
42. Efficient early and sustained transduction of human fetal mesencephalon using adeno-associated virus type 2 vectors.
Tenenbaum L; Peschanski M; Melas C; Rodesh F; Lehtonen E; Stathopoulos A; Velu T; Brotchi J; Levivier M
Cell Transplant; 2004; 13(5):565-71. PubMed ID: 15565868
[TBL] [Abstract][Full Text] [Related]
43. Gene therapy methods in bone and joint disorders. Evaluation of the adeno-associated virus vector in experimental models of articular cartilage disorders, periprosthetic osteolysis and bone healing.
Ulrich-Vinther M
Acta Orthop Suppl; 2007 Apr; 78(325):1-64. PubMed ID: 17427340
[TBL] [Abstract][Full Text] [Related]
44. Viral-mediated gene transfer for cancer treatment.
Wilson DR
Curr Pharm Biotechnol; 2002 Jun; 3(2):151-64. PubMed ID: 12022258
[TBL] [Abstract][Full Text] [Related]
45. Gene delivery in renal tubular epithelial cells using recombinant adeno-associated viral vectors.
Chen S; Agarwal A; Glushakova OY; Jorgensen MS; Salgar SK; Poirier A; Flotte TR; Croker BP; Madsen KM; Atkinson MA; Hauswirth WW; Berns KI; Tisher CC
J Am Soc Nephrol; 2003 Apr; 14(4):947-58. PubMed ID: 12660329
[TBL] [Abstract][Full Text] [Related]
46. Gene delivery and gene therapy with herpes simplex virus-based vectors.
Latchman DS
Gene; 2001 Feb; 264(1):1-9. PubMed ID: 11245972
[TBL] [Abstract][Full Text] [Related]
47. Adeno-associated virus vectors for gene transfer to the brain.
Okada T; Nomoto T; Shimazaki K; Lijun W; Lu Y; Matsushita T; Mizukami H; Urabe M; Hanazono Y; Kume A; Muramatsu S; Nakano I; Ozawa K
Methods; 2002 Oct; 28(2):237-47. PubMed ID: 12413422
[TBL] [Abstract][Full Text] [Related]
48. Advances in recombinant adeno-associated viral vectors for gene delivery.
Petrs-Silva H; Linden R
Curr Gene Ther; 2013 Oct; 13(5):335-45. PubMed ID: 24060313
[TBL] [Abstract][Full Text] [Related]
49. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.
Mandel RJ; Manfredsson FP; Foust KD; Rising A; Reimsnider S; Nash K; Burger C
Mol Ther; 2006 Mar; 13(3):463-83. PubMed ID: 16412695
[TBL] [Abstract][Full Text] [Related]
50. Toward exascale production of recombinant adeno-associated virus for gene transfer applications.
Cecchini S; Negrete A; Kotin RM
Gene Ther; 2008 Jun; 15(11):823-30. PubMed ID: 18401433
[TBL] [Abstract][Full Text] [Related]
51. A new method for recombinant adeno-associated virus vector delivery to murine diaphragm.
Mah C; Fraites TJ; Cresawn KO; Zolotukhin I; Lewis MA; Byrne BJ
Mol Ther; 2004 Mar; 9(3):458-63. PubMed ID: 15006614
[TBL] [Abstract][Full Text] [Related]
52. An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells.
Haridhasapavalan KK; Borgohain MP; Dey C; Saha B; Narayan G; Kumar S; Thummer RP
Gene; 2019 Feb; 686():146-159. PubMed ID: 30472380
[TBL] [Abstract][Full Text] [Related]
53. Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases (review).
Athanasopoulos T; Fabb S; Dickson G
Int J Mol Med; 2000 Oct; 6(4):363-75. PubMed ID: 10998427
[TBL] [Abstract][Full Text] [Related]
54. Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells.
Lopes-Pacheco M; Kitoko JZ; Morales MM; Petrs-Silva H; Rocco PRM
Exp Cell Res; 2018 Nov; 372(2):99-107. PubMed ID: 30244179
[TBL] [Abstract][Full Text] [Related]
55. Gene therapy for Parkinson's disease.
Mochizuki H; Mizuno Y
J Neural Transm Suppl; 2003; (65):205-13. PubMed ID: 12946058
[TBL] [Abstract][Full Text] [Related]
56. [Integration of AAV vectors and insertional mutagenesis].
Rossi A; Salvetti A
Med Sci (Paris); 2016 Feb; 32(2):167-74. PubMed ID: 26936174
[TBL] [Abstract][Full Text] [Related]
57. Noninvasive Imaging Reveals Stable Transgene Expression in Mouse Airways After Delivery of a Nonintegrating Recombinant Adeno-Associated Viral Vector.
Vidović D; Gijsbers R; Quiles-Jimenez A; Dooley J; Van den Haute C; Van der Perren A; Liston A; Baekelandt V; Debyser Z; Carlon MS
Hum Gene Ther; 2016 Jan; 27(1):60-71. PubMed ID: 26567984
[TBL] [Abstract][Full Text] [Related]
58. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access.
Mohan RR; Schultz GS; Hong JW; Mohan RR; Wilson SE
Exp Eye Res; 2003 Mar; 76(3):373-83. PubMed ID: 12573666
[TBL] [Abstract][Full Text] [Related]
59. Differential Effect of Neuropeptides on Excitatory Synaptic Transmission in Human Epileptic Hippocampus.
Ledri M; Sørensen AT; Madsen MG; Christiansen SH; Ledri LN; Cifra A; Bengzon J; Lindberg E; Pinborg LH; Jespersen B; Gøtzsche CR; Woldbye DP; Andersson M; Kokaia M
J Neurosci; 2015 Jul; 35(26):9622-31. PubMed ID: 26134645
[TBL] [Abstract][Full Text] [Related]
60. Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease.
Roy K; Stein L; Kaushal S
Hum Gene Ther; 2010 Aug; 21(8):915-27. PubMed ID: 20384478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
